Scarica l'app Stockscreener
142.14
1.05%
-1.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$143.66
Aprire:
$144.05
Volume 24 ore:
851.85K
Relative Volume:
0.53
Capitalizzazione di mercato:
$20.83B
Reddito:
$9.61B
Utile/perdita netta:
$1.53B
Rapporto P/E:
13.60
EPS:
10.453
Flusso di cassa netto:
$1.85B
1 W Prestazione:
-4.99%
1M Prestazione:
-1.06%
6M Prestazione:
+23.30%
1 anno Prestazione:
-24.79%
Intervallo 1D:
$141.70
$147.48
Intervallo di 1 settimana:
$141.70
$150.20
Portata 52W:
$110.03
$191.19
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
142.09 | 21.30B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
820.00 | 728.24B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
192.18 | 459.63B | 92.15B | 25.12B | 18.18B | 10.36 |
|
ABBV
Abbvie Inc
|
226.99 | 404.77B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
130.88 | 252.16B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
83.88 | 211.56B | 63.43B | 16.42B | 14.72B | 6.4861 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-25 | Iniziato | Jefferies | Buy |
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
(BIIB) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
When is the best time to exit Biogen Inc.July 2025 Review & Capital Protection Trading Alerts - newser.com
Is a relief rally coming for Biogen Inc. holdersMarket Risk Analysis & High Accuracy Swing Entry Alerts - newser.com
Is Biogen Inc. stock a safe buy before earningsJuly 2025 Drop Watch & Stepwise Trade Execution Plans - newser.com
Autoinjectors Market 2025: Industry Drug Delivery, Smart - openPR.com
Sector ETF performance correlation with Biogen Inc.July 2025 Weekly Recap & Free Daily Entry Point Trade Alerts - newser.com
Key metrics from Biogen Inc.’s quarterly dataMarket Activity Report & Fast Moving Stock Watchlists - newser.com
Using portfolio simulators with Biogen Inc. includedInsider Selling & AI Powered Trade Plan Recommendations - newser.com
Is Biogen Inc. (IDP) stock a buy on weaknessPortfolio Update Report & Real-Time Chart Pattern Alerts - newser.com
Biogen (BIIB) Valuation: Assessing Market Discount After Recent Signs of Financial Stabilization - simplywall.st
Biogen (BIIB) to Report Q3 Earnings Amid IPR&D Expense Impact - GuruFocus
Biogen sees negative impact on Q3 EPS from IPR&D expense - Seeking Alpha
Biogen expects $2 million research and development expense in Q3 2025 - Investing.com India
Biogen expects estimated charge to impact net income per diluted share for Q3 by $-0.01 - MarketScreener
CD40 Targeting Therapy Clinical Trials Anti CD40 Antibody Therapy Market Opportunity Assessment Insight - GlobeNewswire Inc.
Wedbush Raises Price Target on Biogen to $135 From $129, Keeps Neutral Rating - MarketScreener
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - ACN Newswire
Can Biogen Inc. stock double in next 5 yearsProduct Launch & Stepwise Entry/Exit Trade Alerts - newser.com
Volatility clustering patterns for Biogen Inc.Weekly Profit Analysis & Real-Time Sentiment Analysis - newser.com
1 Healthcare Stock to Research Further and 2 We Find Risky - FinancialContent
Eisai and Biogen's LEQEMBI IQLIK™ Named One of TIME's "Best Inventions of 2025" for Alzheimer's Treatment - Quiver Quantitative
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - PR Newswire
Is Biogen Inc. stock a top momentum playTrade Risk Assessment & Capital Efficiency Focused Ideas - newser.com
Biogen Inc. (BIIB) Stock Analysis: Exploring a 17% Potential Upside Amidst Robust Neurological Portfolio - DirectorsTalk Interviews
Valeo Financial Advisors LLC Invests $225,000 in Biogen Inc. $BIIB - MarketBeat
UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know - The Globe and Mail
BIIB: Morgan Stanley Raises Price Target for Biogen to $149 | BI - GuruFocus
Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines? - Yahoo Finance
Biogen and Stoke add to zorevunersen data package in Dravet syndrome - The Pharma Letter
Biogen Inc.'s (NASDAQ:BIIB) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue? - 富途牛牛
Biogen, Stoke Therapeutics Present Positive Long-Term Data for Zorevunersen in Dravet Syndrome - MarketScreener
Q3 Earnings Estimate for Biogen Issued By Leerink Partnrs - MarketBeat
Using data filters to optimize entry into Biogen Inc.2025 EndofYear Setup & Stock Portfolio Risk Control - newser.com
What to Expect From Biogen’s Q3 2025 Earnings Report - MSN
Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace
Biogen And Stoke Therapeutics Present Promising Long-Term Data For Zorevunersen In Dravet Syndrome - Nasdaq
Biogen (NASDAQ:BIIB) Earns Sell (D+) Rating from Weiss Ratings - MarketBeat
Biogen invests $250,000 into Durham Tech’s Life Sciences Center - CBS 17
Biogen's (BIIB) Zorevunersen Shows Promise in Treating Dravet Sy - GuruFocus
Biogen and Stoke Therapeutics Announce Positive Long-Term Results of Zorevunersen in Dravet Syndrome at Child Neurology Society Annual Meeting - Quiver Quantitative
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome - Biogen
Stoke Therapeutics, Inc. and Biogen Inc. Present New Data at the 54th Child Neurology Society Annual Meeting That Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome - MarketScreener
Where Does Biogen Stand After Recent 7% Rally Amid Alzheimer’s Drug Developments? - simplywall.st
RBC Capital Sticks to Its Buy Rating for Biogen (BIIB) - The Globe and Mail
Biogen's Comeback: Why The Bulls Are Finally Winning Again (NASDAQ:BIIB) - Seeking Alpha
NC governor recognizes Biogen milestone as biotech giant celebrates recent investments in Triangle - CBS 17
Is Biogen Inc. (IDP) stock a defensive play amid uncertainty2025 Fundamental Recap & Weekly High Return Forecasts - newser.com
Biogen Pledges $250,000 Donation to Durham Technical Community College to Mark 30th Year Anniversary in Research Triangle Park - Biogen
Eisai and Biogen Leqembi Iqlik: The Best Inventions of 2025 - Time Magazine
Simplicity Wealth LLC Makes New $430,000 Investment in Biogen Inc. $BIIB - MarketBeat
Why Are Analysts Bullish on Biogen Inc. (BIIB) Now? - MSN
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Biogen Inc Azioni (BIIB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Singhal Priya | Head of Development |
Aug 29 '25 |
Option Exercise |
0.00 |
1,669 |
0 |
7,096 |
| Singhal Priya | Head of Development |
Sep 02 '25 |
Sale |
133.55 |
517 |
69,045 |
5,772 |
2.22%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):